세계의 다중암 스크리닝 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 검사 유형별, 기술별, 샘플별, 방법별, 암 유형별, 용도별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)
Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Technology, By Sample, By Method, By Cancer Type, By Application, By End User, By Region and Competition, 2020-2030F
상품코드:1728071
리서치사:TechSci Research
발행일:2025년 05월
페이지 정보:영문 189 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 다중암 스크리닝 시장은 2024년 14억 1,000만 달러로 평가되었고, 2030년에는 32억 9,000만 달러에 이를 것으로 예측되며, 예측 기간 중 CAGR은 15.12%를 나타낼 전망입니다.
이 시장은 조기 암 검진에 대한 인식 향상, 다양한 암 유형의 발생률 증가, 유전체 분석 기술의 발전에 힘입어 급속히 성장하고 있습니다. 의료 시스템은 액체 생검, 차세대 시퀀싱(NGS), 다중 암 검진을 동시에 가능하게 하는 AI 통합 생물정보학 플랫폼 등 비침습적 조기 검진 방법에 대한 투자를 확대하고 있습니다.
시장 개요
예측 기간
2026-2030년년
시장 규모(2024년)
14억 1,000만 달러
시장 규모(2030년)
32억 9,000만 달러
CAGR(2025-2030년)
15.12%
급성장 부문
소화기
최대 시장
북미
정부 지원 프로그램 및 국제 자금 지원 프로젝트는 연구 및 상업화 속도를 더욱 가속화하고 있습니다. 진단 개발업체와 학술 기관 간의 전략적 파트너십은 강력한 임상 검증과 광범위한 채택을 촉진하고 있습니다. 이러한 노력은 예방 의료 및 인구 수준 검진 전략으로의 전환과 결합되어 선진국과 신흥 시장 모두에서 다중암 조기 검출(MCED) 검사의 강력한 성장 동력을 창출하고 있습니다.
주요 시장 성장 촉진요인
만성 질환의 유병률 증가
주요 시장 과제
표준화 및 임상 검증 부족
주요 시장 동향
액체 생검 및 유전체 기술의 통합
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 다중암 스크리닝 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
검사 유형별(실험실 개발 검사(LDTs), 체외 진단(IVD))
기술별(차세대 시퀀싱(NGS), 중합효소 연쇄반응(PCR), 면역조직화학(IHC), 형광 현미경 조직 검사 (FISH), 기타)
The Global Multicancer Screening Market was valued at USD 1.41 billion in 2024 and is projected to reach USD 3.29 billion by 2030, registering a CAGR of 15.12% during the forecast period. The market is expanding rapidly, supported by heightened awareness around early cancer detection, growing incidence rates of various cancer types, and technological advancements in genomic analysis. Healthcare systems are increasingly investing in non-invasive early detection methods, including liquid biopsy, next-generation sequencing (NGS), and AI-integrated bioinformatics platforms that facilitate screening for multiple cancers simultaneously.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 1.41 Billion
Market Size 2030
USD 3.29 Billion
CAGR 2025-2030
15.12%
Fastest Growing Segment
Gastrointestinal
Largest Market
North America
Government-backed initiatives, such as the Cancer Moonshot program and other international funding projects, are further accelerating research and commercial deployment. Strategic partnerships between diagnostic developers and academic institutions are fostering robust clinical validation and broader adoption. These efforts, combined with the shift toward preventive care and population-level screening strategies, are driving strong momentum for multicancer early detection (MCED) tests in both developed and emerging markets.
Key Market Drivers
Increasing Prevalence of Chronic Diseases
The growing global burden of cancer continues to be a major driver for the multicancer screening market. Rising incidences of cancer types such as breast, lung, colorectal, prostate, and stomach cancer are fueling the demand for comprehensive screening solutions. For example, in 2023 alone, approximately 300,590 new cases of breast cancer were diagnosed in the U.S. According to the World Health Organization, global cancer data from 2020 showed 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, and over 1 million cases each for colon, prostate, skin (non-melanoma), and stomach cancers.
Countries like Denmark, Ireland, and Australia continue to record some of the highest cancer incidence rates globally, indicating a pressing need for early, accurate, and efficient detection methods. Multicancer screening platforms offer the potential to identify a wide array of cancers at earlier stages, improving prognosis and reducing mortality rates. As cancer rates rise, especially in aging and urbanizing populations, the need for reliable MCED solutions will continue to grow, reinforcing market demand.
Key Market Challenges
Lack of Standardization and Clinical Validation
One of the primary challenges faced by the multicancer screening market is the lack of harmonized standards and comprehensive clinical validation for newer screening tests. Despite significant innovation, the absence of universal testing protocols and diagnostic benchmarks across geographies leads to inconsistent results, limiting test reliability. Without standardized procedures, healthcare providers may remain cautious in adopting multicancer screening technologies.
Moreover, many MCED platforms lack validation through large-scale clinical trials, which are essential for establishing clinical efficacy, sensitivity, and specificity. Regulatory agencies demand substantial evidence before approving these tools for widespread use. Without such validation, uncertainty persists regarding the accuracy and practical application of these tests in real-world settings. This slows down market adoption and hinders regulatory acceptance, particularly in diverse population groups with varying risk profiles.
Key Market Trends
Integration of Liquid Biopsy and Genomic Technologies
A prominent trend shaping the multicancer screening landscape is the convergence of liquid biopsy and advanced genomic technologies. Liquid biopsy methods analyze biomarkers such as circulating tumor DNA (ctDNA), RNA, and exosomes from blood or other fluids, offering a minimally invasive approach to early cancer detection. These techniques allow for cancer identification even before symptoms emerge, and they support ongoing disease monitoring and treatment assessment.
When paired with high-throughput genomic tools such as next-generation sequencing (NGS), the accuracy and scope of liquid biopsy expand significantly. NGS enables comprehensive mutation analysis and enhances the detection of multiple cancer types from a single sample. As these technologies become more cost-effective and refined, their adoption is increasing for large-scale, multi-cancer screening. This integration improves test efficiency, reduces patient burden, and supports broader implementation of population-wide cancer detection programs.
Key Market Players
Agilent Technologies, Inc.
Atara Biotherapeutics, Inc.
Burning Rock Biotech Limited
Exact Sciences Corporation
F. Hoffmann-La Roche Ltd.
Fulgent Genetics, Inc.
Genecast Biotechnology Co., Ltd.
Guardant Health, Inc.
Illumina, Inc.
Konica Minolta, Inc.
Report Scope
In this report, the Global Multicancer Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Multicancer Screening Market, By Test Type:
Laboratory Developed Tests (LDTs)
In-Vitro Diagnostics (IVDs)
Multicancer Screening Market, By Technology:
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
Fluorescence In-Situ Hybridization (FISH)
Others
Multicancer Screening Market, By Sample:
Tissue
Blood
Saliva and Buccal Swab
Others
Multicancer Screening Market, By Method:
DNA
RNA
Proteins
Multicancer Screening Market, By Cancer Type:
Breast and Gynecologic
Gastrointestinal
Endocrine
Genitourinary
Skin
Brain/Nervous System
Sarcoma
Hematological Malignancies
Lung
Head and Neck
Other Cancer Types
Multicancer Screening Market, By Application:
Clinical
Research
Multicancer Screening Market, By End User:
Hospitals
Diagnostic and Clinical Laboratories
Academic Research Institutions
Others
Multicancer Screening Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Multicancer Screening Market.
Available Customizations
Global Multicancer Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Multicancer Screening Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, Others)
5.2.4. By Method (DNA, RNA, Proteins)
5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, Other Cancer Types)
5.2.6. By Application (Clinical, Research)
5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, Others)
5.2.8. By Company (2024)
5.2.9. By Region
5.3. Market Map
6. North America Multicancer Screening Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Technology
6.2.3. By Sample
6.2.4. By Method
6.2.5. By Cancer Type
6.2.6. By Application
6.2.7. By End User
6.2.8. By Country
6.3. North America: Country Analysis
6.3.1. United States Multicancer Screening Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Sample
6.3.1.2.4. By Method
6.3.1.2.5. By Cancer Type
6.3.1.2.6. By Application
6.3.1.2.7. By End User
6.3.2. Mexico Multicancer Screening Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Sample
6.3.2.2.4. By Method
6.3.2.2.5. By Cancer Type
6.3.2.2.6. By Application
6.3.2.2.7. By End User
6.3.3. Canada Multicancer Screening Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Sample
6.3.3.2.4. By Method
6.3.3.2.5. By Cancer Type
6.3.3.2.6. By Application
6.3.3.2.7. By End User
7. Europe Multicancer Screening Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Technology
7.2.3. By Sample
7.2.4. By Method
7.2.5. By Cancer Type
7.2.6. By Application
7.2.7. By End User
7.2.8. By Country
7.3. Europe: Country Analysis
7.3.1. France Multicancer Screening Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Sample
7.3.1.2.4. By Method
7.3.1.2.5. By Cancer Type
7.3.1.2.6. By Application
7.3.1.2.7. By End User
7.3.2. Germany Multicancer Screening Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Sample
7.3.2.2.4. By Method
7.3.2.2.5. By Cancer Type
7.3.2.2.6. By Application
7.3.2.2.7. By End User
7.3.3. United Kingdom Multicancer Screening Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Test Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Sample
7.3.3.2.4. By Method
7.3.3.2.5. By Cancer Type
7.3.3.2.6. By Application
7.3.3.2.7. By End User
7.3.4. Italy Multicancer Screening Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Sample
7.3.4.2.4. By Method
7.3.4.2.5. By Cancer Type
7.3.4.2.6. By Application
7.3.4.2.7. By End User
7.3.5. Spain Multicancer Screening Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Sample
7.3.5.2.4. By Method
7.3.5.2.5. By Cancer Type
7.3.5.2.6. By Application
7.3.5.2.7. By End User
8. Asia-Pacific Multicancer Screening Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Technology
8.2.3. By Sample
8.2.4. By Method
8.2.5. By Cancer Type
8.2.6. By Application
8.2.7. By End User
8.2.8. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Multicancer Screening Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Sample
8.3.1.2.4. By Method
8.3.1.2.5. By Cancer Type
8.3.1.2.6. By Application
8.3.1.2.7. By End User
8.3.2. India Multicancer Screening Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Sample
8.3.2.2.4. By Method
8.3.2.2.5. By Cancer Type
8.3.2.2.6. By Application
8.3.2.2.7. By End User
8.3.3. South Korea Multicancer Screening Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Sample
8.3.3.2.4. By Method
8.3.3.2.5. By Cancer Type
8.3.3.2.6. By Application
8.3.3.2.7. By End User
8.3.4. Japan Multicancer Screening Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Sample
8.3.4.2.4. By Method
8.3.4.2.5. By Cancer Type
8.3.4.2.6. By Application
8.3.4.2.7. By End User
8.3.5. Australia Multicancer Screening Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Sample
8.3.5.2.4. By Method
8.3.5.2.5. By Cancer Type
8.3.5.2.6. By Application
8.3.5.2.7. By End User
9. South America Multicancer Screening Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Technology
9.2.3. By Sample
9.2.4. By Method
9.2.5. By Cancer Type
9.2.6. By Application
9.2.7. By End User
9.2.8. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Multicancer Screening Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Sample
9.3.1.2.4. By Method
9.3.1.2.5. By Cancer Type
9.3.1.2.6. By Application
9.3.1.2.7. By End User
9.3.2. Argentina Multicancer Screening Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Sample
9.3.2.2.4. By Method
9.3.2.2.5. By Cancer Type
9.3.2.2.6. By Application
9.3.2.2.7. By End User
9.3.3. Colombia Multicancer Screening Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Sample
9.3.3.2.4. By Method
9.3.3.2.5. By Cancer Type
9.3.3.2.6. By Application
9.3.3.2.7. By End User
10. Middle East and Africa Multicancer Screening Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Test Type
10.2.2. By Technology
10.2.3. By Sample
10.2.4. By Method
10.2.5. By Cancer Type
10.2.6. By Application
10.2.7. By End User
10.2.8. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Multicancer Screening Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Sample
10.3.1.2.4. By Method
10.3.1.2.5. By Cancer Type
10.3.1.2.6. By Application
10.3.1.2.7. By End User
10.3.2. Saudi Arabia Multicancer Screening Market Outlook
